VRDN Stock Analysis: Buy, Sell, or Hold?
VRDN - Viridian Therapeutics, Inc. Common Stock
$17.90
0.51 (2.93%)
▲
5d:
+7.64%
30d:
+3.71%
90d:
-36.52%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.0/10
Get Alerted When VRDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VRDN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VRDN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VRDN is currently trading at $17.90, which is considered extended relative to its 30-day fair value range of $16.06 to $17.43.
Technical Outlook: Technically, VRDN is in a strong uptrend. The price is approaching resistance at $18.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VRDN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.94 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VRDN is in a strong uptrend. The price is approaching resistance at $18.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VRDN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.94 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.06 -
$17.43
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.6% below Wall St target ($33.94)
Trading Range Analysis
30-Day Trading Range
$16.06 -
$17.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$15.96
Resistance Level
$18.38
Current Trend
Strong Uptrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.13
Wall Street Target
$33.94
(+89.6%)
Revenue Growth (YoY)
95.8%
Share & Embed Analysis
Last updated: June 28, 2026 1:01 PM ET
Data refreshes hourly during market hours. Next update: 2:01 PM
Data refreshes hourly during market hours. Next update: 2:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jennifer Tousignant
SELL
2272 shares
2025-12-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 60 BUY |
Advanced VRDN Option Strategies
Professional options setups generated by AI based on today's VRDN price and gamma walls.
